{"id":"NCT00048724","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)","officialTitle":"PEG-Intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects With Compensated Cirrhosis (METAVIR F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Alpha Interferon Plus Ribavirin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-06","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2002-11-08","resultsPosted":"2009-06-11","lastUpdate":"2017-04-04"},"enrollment":631,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C","Cirrhosis"],"interventions":[{"type":"BIOLOGICAL","name":"peginterferon alfa-2b (SCH 54031)","otherNames":["PegIntron"]}],"arms":[{"label":"PegIntron","type":"EXPERIMENTAL"},{"label":"Untreated Control","type":"NO_INTERVENTION"}],"summary":"The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no treatment for the prevention of disease progression in adult subjects with compensated cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a interferon plus ribavirin.","primaryOutcome":{"measure":"Time to Observation of the First Clinical Event Experienced by a Subject","timeFrame":"Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event","effectByArm":[{"arm":"PegIntron","deltaMin":3,"sd":null},{"arm":"Untreated Control","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1439"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21419770"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":93,"n":311},"commonTop":["FATIGUE","HEADACHE","ARTHRALGIA","SPLENOMEGALY","HEPATOMEGALY"]}}